In a study involving 16 patients, a drug designed to treat immune system disorders, halted the progression of Alzheimer’s disease over three years. This trial marks a significant breakthrough in combating a condition that deeply impacts both patients and their loved ones. Here’s what you need to know about the drug Gammagard:
1. **Effectiveness**:
Gammagard’s effectiveness is truly remarkable. Out of all the patients, only those who received an intermediate dose experienced benefits. Patients who received other doses or a placebo saw no improvements. While the exact way Gammagard works is not fully understood, it is known to prevent the formation of beta-amyloid, a key factor in Alzheimer’s. This specific dosage helps stop the worsening symptoms of the disease.
2. **Alzheimer’s Progression**:
Gammagard hasn’t been shown to reverse Alzheimer’s, but it has been successful in halting its progress. Patients on the intermediate dose have remained in the mild stages of the disease for years, enjoying a better quality of life than usually seen in Alzheimer’s patients. Even those initially given a placebo experienced halted mental decline once they switched to the intermediate dose of Gammagard.
3. **Side Effects**:
There are serious side effects associated with Gammagard, especially for patients sensitive to Immunoglobulin A or prone to anaphylactic reactions. Common side effects include renal failure, aseptic meningitis, and spontaneous blood clotting. Patients must weigh these potential risks against the benefits.
4. **Availability**:
Gammagard is not expected to be widely available until mid-2013 at the earliest. FDA approval requires evidence of safety and effectiveness from a larger study involving 390 people, which is currently underway. Once approved, the drug will be available by prescription only.
5. **Cost**:
Details on the cost of Gammagard post-FDA approval are not yet available. However, it is already being prescribed off-label in some states, costing about $4,200 per month or $50,000 per year. Insurance does not currently cover Gammagard, although coverage is anticipated after official approval.
While the current cost of Gammagard is prohibitive for many, the promising results from clinical trials offer hope. With continued progress, it’s possible that soon, Alzheimer’s patients may have access to a drug that can halt the disease, allowing families to cherish more time with their loved ones.